NCT00866138View on ClinicalTrials.gov

Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3

PHASE2CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

Multiple Myeloma

Interventions

DRUG

masitinib (AB1010)

masitinib 9 mg/kg/day per os

Trial Locations (1)

Unknown

Hopital Saint Louis, Paris

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AB Science

INDUSTRY